Worth Investment & Trading Company Limited is an Indian financial services entity currently undergoing a fundamental structural and operational transformation. Registered as a **Non-Banking Financial Company (NBFC)** under **Section 45-IA of the Reserve Bank of India Act, 1934** (Registration No. **B.05.03383**), the company is classified as a non-deposit-taking entity (**NBFC-ND-SI**). The company is presently at a strategic crossroads, transitioning from its legacy as a private financier and investment holding firm toward a diversified industrial conglomerate model, while simultaneously addressing significant governance and operational challenges. --- ### Strategic Pivot and Corporate Restructuring The company has initiated a comprehensive "Strategic Reorientation" to move away from its traditional financial services roots and enter high-growth industrial sectors. * **NBFC License Surrender:** In **September 2024**, the Board of Directors formally established a committee to oversee the surrender of its **NBFC License** to the **Reserve Bank of India (RBI)**. * **Industrial Acquisition:** The company is currently evaluating the takeover of **Enam Organics India Limited**. This acquisition is a cornerstone of its plan to pivot toward the chemical and organic sectors. * **Corporate Rebranding:** To align its identity with this new industrial focus, a formal change of the company’s name is under active consideration. * **Operational Status:** As of the latest reporting cycle, the company’s core business operations are **temporarily halted**. Management intends to restart operations in the "near future" once a final product line with superior growth prospects is selected. --- ### Diversified Industrial Mandate While historically focused on finance, the company’s constitutional mandates allow for a broad operational footprint across several industrial verticals. Its future roadmap includes: | Segment | Key Products & Activities | | :--- | :--- | | **Packaging & Containers** | Manufacture and export of **containers, cans, drums, and bottle tops** using **tin, metal, and aluminum**. | | **Agrochemicals & Fertilizers** | Production of **Ammonium Sulphate Nitrate, Urea, and Super Phosphate**; manufacturing of pesticides and processed seeds. | | **Healthcare & Pharma** | Production of **drugs, medicines, capsules, and injections**, alongside surgical appliances and orthopedic stores. | | **Food & Beverages** | Distribution of **dairy products (ghee, cheese), confectionery, flour, and fruit juices**. | | **Consumer Goods** | Manufacturing of personal hygiene products, including **soaps, lotions, and cosmetic preparations** (Allopathic and Ayurvedic). | --- ### Capital Structure and Shareholder Equity The company has aggressively restructured its capital base in **2024** to enhance liquidity and fund its transition. **Key Capital Metrics (Post-Restructuring):** * **Authorised Share Capital:** Increased from **Rs. 16.60 Crore** to **Rs. 37.10 Crore** in **October 2024**. * **Paid-up Equity Capital:** Stood at **Rs. 37,07,17,000** as of **November 2024**, comprising **37,07,17,000** shares at a face value of **Re. 1**. * **Stock Split:** In **May 2024**, the company executed a sub-division of **1** equity share (FV **Rs. 10**) into **10** equity shares (FV **Re. 1**). * **Bonus Issue:** In **November 2024**, the company allotted **22,24,30,200** shares in a **1.5:1** ratio (**3** new shares for every **2** held), capitalizing **Rs. 24.35 Crore** from free reserves. **Historical Capital Evolution:** | Metric | FY 2023-24 (March 31) | FY 2022-23 (March 31) | |:---|:---|:---| | **Paid-up Equity Capital** | **Rs. 10,02,86,800** | **Rs. 6,33,00,000** | | **Total Equity Shares** | **1,00,28,680** (Rs. 10 FV) | **63,30,000** (Rs. 10 FV) | | **Dividend Recommended** | **NIL** | **NIL** | --- ### Financial Resource Management The company has utilized preferential allotments and warrant conversions to manage debt and fund corporate actions. * **Preferential Issue (Nov 2023):** Allotted **36,98,680** equity shares and **48,00,000** convertible warrants at **Rs. 24.50** (including a **Rs. 14.50** premium). * **Warrant Conversion:** On **April 18, 2024**, warrants were converted to equity, bringing in significant capital. * **Fund Deployment:** * **₹964.91 Lacs** utilized for **Bonus** issues. * **₹480 Lacs** utilized for **Loan Repayment**. * **Finance Cost Reversal:** In **December 2023**, the company recorded a negative finance cost of **₹37,45,223** following a write-off of interest payable after receiving confirmations from creditors. --- ### Governance, Management, and Internal Controls The Board of Directors consists of **3 to 12 members**, with **two-thirds** subject to retirement by rotation. While the leadership possesses expertise in **General Management, Finance, and Law**, recent audits have highlighted significant governance gaps. * **Key Appointments:** **Mr. Lalit Tulsiani** was re-appointed as an Independent Director for a second term (**2024–2029**). * **Audit Deficiencies:** Secretarial filings for **FY 2024-25** noted that internal audit reports and performance evaluations were not received for verification. * **Internal Control Lapses:** * **Related Party Transactions:** Loans were granted to related parties and sister concerns (notably **Aarey Drugs and Pharmaceuticals Limited**) without requisite Board or Committee approvals. * **Insider Trading Compliance:** Failure to maintain an independent **Structured Digital Database (SDD)**; the server was shared with a group company, compromising the tracking of **Unpublished Price Sensitive Information (UPSI)**. * **Secretarial Failures:** The Company Secretary failed to attend key meetings, and detailed agenda notes were not provided as per **Secretarial Standard-1**. --- ### Risk Profile and Compliance Outlook Investors should note that the company is exposed to high regulatory and macroeconomic risks. * **Regulatory Non-Compliance:** The company has faced delays in filing **Integrated Financials (Dec 2024)**, **Form MGT-14**, and mandatory **RBI forms (DNBS10)**. It also failed to provide clarifications to the **BSE** regarding unusual price movements in **May 2022**. * **Macroeconomic Sensitivity:** Performance is highly susceptible to **inflation**, **Indian Rupee (INR) depreciation**, and fluctuations in **RBI REPO rates**. * **Liquidity and Solvency:** While certified as capable of meeting liabilities within a **one-year period** from the balance sheet date, the lack of active operations creates an inherent liquidity risk. * **Investor Relations:** The company has not yet opened a **'Suspense Escrow Demat Account'** for physical shares and maintains a website that is not fully compliant with **SEBI** mandatory policy disclosures.